

BCHE Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP7829c**Specification**

BCHE Antibody (Center) Blocking Peptide - Product InformationPrimary Accession [P06276](#)**BCHE Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 590**Other Names**

Cholinesterase, Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, Pseudocholinesterase, BCHE, CHE1

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7829c](/products/AP7829c) was selected from the Center region of human BCHE. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

BCHE Antibody (Center) Blocking Peptide - Protein Information**Name** BCHE**Synonyms** CHE1**Function**

Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.

Cellular Location

Secreted

Tissue Location

Detected in blood plasma (at protein level). Present in most cells except erythrocytes

BCHE Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

BCHE Antibody (Center) Blocking Peptide - Images

BCHE Antibody (Center) Blocking Peptide - Background

Mutant proteins of BCHE are responsible for suxamethonium sensitivity. Homozygous persons sustain prolonged apnea after administration of the muscle relaxant suxamethonium in connection with surgical anesthesia. The activity of pseudocholinesterase in the serum is low and its substrate behavior is atypical. In the absence of the relaxant, the homozygote is at no known disadvantage.

BCHE Antibody (Center) Blocking Peptide - References

Primo-Parmo S.L., Bartels C.F. Am. J. Hum. Genet. 58:52-64(1996) Primo-Parmo S.L., Lightstone H. Pharmacogenetics 7:27-34(1997) Yen T., Nightingale B.N. Clin. Chem. 49:1297-1308(2003)